KRAS and hepatocellular carcinoma: To investigate the effects of multi‐targeted therapies, we conduct a thorough analysis of metabolic dysregulation in HCC cells targeting KRAS with NSC48160 to identify metabolic vulnerabilities that could be targeted in treating HCC.